Papatestas A E, Lesnick G J
Surg Gynecol Obstet. 1975 Jan;140(1):22-6.
To evaluate the results of treatment of Stage I and Stage II-T1 and T2, NO and N1-carcinoma of the breast by modified radical mastectomy with preservation of the pectoralis major muscle, the survival rates of all such patients treated by the senior author from 1965 through 1968 were compared with the survival rates of a simultaneous group of patients with similar stage disease treated by conventional radical mastectomy by the same surgeon. There were a total of 134 patients, of whom 51 had modified radical mastectomy and 83 conventional radical mastectomy. The five year survival rate for those treated by standard radical mastectomy was 81 per cent, and for those treated by modified radical mastectomy, it was 84 per cent. In patients with histologically negative axillary lymph nodes, the rates were 86 per cent following both radical mastectomy and modified radical mastectomy. Four per cent of the surviving patients after modified radical mastectomy and 7 per cent of the five year survivors after radical mastectomy had evidence of metastases at five years. Locally recurrent disease was noted in 5 per cent of those who had modified radical mastectomy and 7 per cent of those who underwent standard radical mastectomy. This analysis demonstrates that there is no significant difference in the survival and recurrence rates after conventional radical mastectomy and ,odified radical mastectomy of the Patey type. There is a high incidence of recurrence-free survival after both of these operations. Since modified radical mastectomy is less traumatic, involving less damage to muscular tissues, and is followed by significantly decreased deformity, it is advised as the treatment of choice for patients with carcinoma of the breast having no or minimal evidence of axillary node involvement. More extensive tumors adherent to the pectoral fascia or associated with multiple or large palpable axillary nodes should still be treated by conventional radical mastectomy.
为评估保留胸大肌的改良根治性乳房切除术治疗Ⅰ期和Ⅱ - T1及T2、NO和N1期乳腺癌的效果,将1965年至1968年资深作者治疗的所有此类患者的生存率,与同一外科医生同期采用传统根治性乳房切除术治疗的相似分期疾病患者的生存率进行比较。共有134例患者,其中51例行改良根治性乳房切除术,83例行传统根治性乳房切除术。标准根治性乳房切除术治疗患者的五年生存率为81%,改良根治性乳房切除术治疗患者的五年生存率为84%。在腋窝淋巴结组织学阴性的患者中,根治性乳房切除术和改良根治性乳房切除术后的生存率均为86%。改良根治性乳房切除术后存活患者中有4%、根治性乳房切除术后五年存活患者中有7%在五年时有转移证据。改良根治性乳房切除术患者中有5%出现局部复发病例,标准根治性乳房切除术患者中有7%出现局部复发病例。该分析表明,传统根治性乳房切除术和佩蒂(Patey)型改良根治性乳房切除术后的生存率和复发率无显著差异。这两种手术术后无复发生存率均较高。由于改良根治性乳房切除术创伤较小,对肌肉组织损伤较小,术后畸形明显减轻,因此建议将其作为腋窝淋巴结无受累或仅有轻微受累证据的乳腺癌患者的首选治疗方法。对于与胸肌筋膜粘连或伴有多个可触及的大腋窝淋巴结的更广泛肿瘤,仍应采用传统根治性乳房切除术治疗。